Platelet function and antiplatelet therapy

British Journal of Surgery

Volumn 94, Issue 6, 2007, Pages 674-682

  Troxler, M ^a   Dickinson, K ^a   Homer Vanniasinkam, S ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINOSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; COLLAGEN; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THROMBIN; THROMBOXANE A2; TICLOPIDINE;

ANTIMICROBIAL ACTIVITY; ATHEROSCLEROSIS; BLEEDING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CROHN DISEASE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DYSPEPSIA; ENTERITIS; GASTROINTESTINAL HEMORRHAGE; HEMOSTASIS; HUMAN; INFLAMMATION; META ANALYSIS; MONOTHERAPY; PATHOGENESIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTOSIS; THROMBOSIS; TUMOR GROWTH;

ATHEROSCLEROSIS; BLOOD PLATELETS; HEMOSTASIS; HUMANS; INFLAMMATORY BOWEL DISEASES; NEOPLASM METASTASIS; NEOPLASMS; PLATELET AGGREGATION INHIBITORS;

EID: 34250367933     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.5852     Document Type: Review

References (73)

1. Coller BS. Foreword: a brief and selective history of ideas about platelets in health and disease. In Platelets, Michelson AD (ed.). Academic Press: Amsterdam, 2002; xxix-xliii.
2. Wu KK. Platelet activation mechanisms and markers in arterial thrombosis. J Intern Med 1996; 239: 17-34.
3. Clinical use of blood products in medical conditions. In Handbook of Transfusion Medicine: Blood Transfusion Services of the United Kingdom, McClelland DBL (ed.). The Stationery Office: London, 2001; 59-70.
4. Klinger MH. Platelets and inflammation. Anat Embryol (Berl) 1997; 196: 1-11.
5. Sixma JJ, Slot JW, Geuze HJ. Immunocytochemical localization of platelet granule proteins. Methods Enzymol 1989; 169: 301-311.
6. 111In-labelled human platelets. Eur J Nucl Med 1985; 10: 522-527.
7. Hanson SR, Slichter SJ. Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood 1985; 66: 1105-1109.
8. van Zanten GH, de Groot PG, Sixma JJ. Platelet adhesion. In Platelets and Their Factors, von Bruchhausen F, Walter U (eds). Springer: Berlin, 1997; 61-81.
9. Yuan Y, Kulkarni S, Ulsemer P, Cranmer SL, Yap CL, Nesbitt WS et al. The von Willebrand factor-glycoprotein Ib/V/IX interaction induces actin polymerization and cytoskeletal reorganization in rolling platelets and glycoprotein Ib/V/IX-transfected cells. J Biol Chem 1999; 274: 36241-36251.
10. Dore M. Platelet-leukocyte interactions. Am Heart J 1998; 135: S146-S151.
11. McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost 2001; 86: 746-756.
12. Sixma JJ, van Zanten GH, Huizinga EG, van der Plas RM, Verkley M, Wu YP et al. Platelet adhesion to collagen: an update. Thromb Haemost 1997; 78: 434-438.
13. Ruf A, Frojmovic MM, Patscheke H. Platelet aggregation. In Platelets and Their Factors, von Bruchhausen F, Walter U (eds). Springer: Berlin, 1997; 83-98.
14. Matsagas MI, Geroulakos G, Mikhailidis DP. The role of platelets in peripheral arterial disease: therapeutic implications. Ann Vasc Surg 2002; 16: 246-258.
15. Clemetson KJ, Polgar J. Platelet adhesion and aggregation receptors. In Platelets and Their Factors, von Bruchhausen F, Walter U (eds). Springer: Berlin, 1997; 155-179.
16. Kulkarni S, Dopheide SM, Yap CL, Ravanat C, Freund M, Mangin P et al. A revised model of platelet aggregation. J Clin Invest 2000; 105: 783-791.
17. Merten M, Thiagarajan P. P-selectin expression on platelets determines size and stability of platelet aggregates. Circulation 2000; 102: 1931-1936.
18. Peterson DM, Stathopoulos NA, Giorgio TD, Hellums JD, Moake JL. Shear-induced platelet aggregation requires von Willebrand factor and platelet membrane glycoproteins Ib and IIb-IIIa. Blood 1987; 69: 625-628.
19. Ruggeri ZM, Dent JA, Saldivar E. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood 1999; 94: 172-178.
20. Muta T, Iwanaga S. The role of hemolymph coagulation in innate immunity. Curr Opin Immunol 1996; 8: 41-47.
21. Cavanagh SP, Gough MJ, Homer-Vanniasinkam S. The role of the neutrophil in ischaemia-reperfusion injury: potential therapeutic interventions. Cardiovasc Surg 1998; 6: 112-118.
22. Diacovo TG, Roth SJ, Buccola JM, Bainton DF, Springer TA. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood 1996; 88: 146-157.
23. May AE, Neumann FJ, Preissner KT. The relevance of blood cell-vessel wall adhesive interactions for vascular thrombotic disease. Thromb Haemost 1999; 82: 962-970.
24. Bazzoni G, Dejana E, Del Maschio A. Platelet-neutrophil interactions. Possible relevance in the pathogenesis of thrombosis and inflammation. Haematologica 1991; 76: 491-499.
25. Celi A, Lorenzet R, Furie B, Furie BC. Platelet-leukocyte-endothelial cell interaction on the blood vessel wall. Semin Hematol 1997; 34: 327-335.
26. Massberg S, Enders G, Leiderer R, Eisenmenger S, Vestweber D, Krombach F et al. Platelet-endothelial cell interactions during ischemia/ reperfusion: the role of P-selectin. Blood 1998; 92: 507-515.
27. Ware JA, Heistad DD. Seminars in medicine of the Beth Israel Hospital, Boston. Platelet-endothelium interactions. N Engl J Med 1993; 328: 628-635.
28. Freedman JE, Loscalzo J, Benoit SE, Valeri CR, Barnard MR, Michelson AD. Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. J Clin Invest 1996; 97: 979-987.
29. Weyrich AS, Elstad MR, McEver RP, McIntyre TM, Moore KL, Morrissey JH et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest 1996; 97: 1525-1534.
30. Nagata K, Tsuji T, Todoroki N, Katagiri Y, Tanoue K, Yamazaki H et al. Activated platelets induce superoxide anion release by monocytes and neutrophils through P-selectin (CD62). J Immunol 1993; 151: 3267-3273.
31. Hegele RA. The pathogenesis of atherosclerosis. Clin Chim Acta 1996; 246: 21-38.
32. Osterud B. A global view on the role of monocytes and platelets in atherogenesis. Thromb Res 1997; 85: 1-22.
33. Collins CE, Cahill MR, Newland AC, Rampton DS. Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology 1994; 106: 840-845.
34. Collins CE, Rampton DS. Review article: platelets in inflammatory bowel disease - pathogenetic role and therapeutic implications. Aliment Pharmacol Ther 1997; 11: 237-247.
35. Carty E, MacEy M, Rampton DS. Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14: 1169-1179.
36. Bensing BA, Rubens CE, Sullam PM. Genetic loci of Streptococcus mitis that mediate binding to human platelets. Infect Immun 2001; 69: 1373-1380.
37. Clawson CC, White JG, Herzberg MC. Platelet interaction with bacteria. VI. Contrasting the role of fibrinogen and fibronectin. Am J Hematol 1980; 9: 43-53.
38. Clawson CC, White JG. Platelet interaction with bacteria. I. Reaction phases and effects of inhibitors. Am J Pathol 1971; 65: 367-380.
39. Saluk-Juszczak J, Wachowicz B, Kaca W. Endotoxins stimulate generation of superoxide radicals and lipid peroxidation in blood platelets. Microbios 2000; 103: 17-25.
40. Yeaman MR, Tang YQ, Shen AJ, Bayer AS, Selsted ME. Purification and in vitro activities of rabbit platelet microbicidal proteins. Infect Immun 1997; 65: 1023-1031.
41. Tang YQ, Yeaman MR, Selsted ME. Antimicrobial peptides from human platelets. Infect Immun 2002; 70: 6524-6533.
42. Yount NY, Gank KD, Xiong YQ, Bayer AS, Pender T, Welch WH et al. Platelet microbicidal protein 1: structural themes of a multifunctional antimicrobial peptide. Antimicrob Agents Chemother 2004; 48: 4395-4404.
43. Xiong YQ, Yeaman MR, Bayer AS. In vitro antibacterial activities of platelet microbicidal protein and neutrophil defensin against Staphylococcus aureus are influenced by antibiotics differing in mechanism of action. Antimicrob Agents Chemother 1999; 43: 1111-1117.
44. Chang FY, Singh N, Gayowski T, Wagener MM, Mietzner SM, Stout JE et al. Thrombocytopenia in liver transplant recipients: predictors, impact on fungal infections, and role of endogenous thrombopoietin. Transplantation 2000; 69: 70-75.
45. Kirkpatrick B, Reeves DS, MacGowan AP. A review of the clinical presentation, laboratory features, antimicrobial therapy and outcome of 77 episodes of pneumococcal meningitis occurring in children and adults. J Infect 1994; 29: 171-182.
46. Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semin Thromb Hemost 2004; 30: 95-108.
47. Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. Lancet Oncol 2004; 5: 655-663.
48. Pedersen LM, Milman N. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J 1996; 9: 1826-1830.
49. Monreal M, Fernandez-Llamazares J, Pinol M, Julian JF, Broggi M, Escola D et al. Platelet count and survival in patients with colorectal cancer - a preliminary study. Thromb Haemost 1998; 79: 916-918.
50. Jurasz P, Alonso-Escolano D, Radomski MW. Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol 2004; 143: 819-826.
51. Chen YQ, Trikha M, Gao X, Bazaz R, Porter AT, Timar J et al. Ectopic expression of platelet integrin alphaIIb beta3 in tumor cells from various species and histological origin. Int J Cancer 1997; 72: 642-648.
52. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005; 105: 178-185.
53. Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999; 59: 1295-1300.
54. Mohle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A 1997; 94: 663-668.
55. Nierodzik ML, Klepfish A, Karpatkin S. Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thromb Haemost 1995; 74: 282-290.
56. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A 2001; 98: 3352-3357.
57. Awtry EH, Loscalzo J. Aspirin. In Platelets, Michelson AD (ed.). Academic Press: Amsterdam, 2002; 745-768.
58. Upchurch GR Jr, Ramdev N, Walsh MT, Loscalzo J. Prothrombotic consequences of the oxidation of fibrinogen and their inhibition by aspirin. J Thromb Thrombolysis 1998; 5: 9-14.
59. Steer KA, Wallace TM, Bolton CH, Hartog M. Aspirin protects low density lipoprotein from oxidative modification. Heart 1997; 77: 333-337.
60. Weber AA, Braun M, Hohlfeld T, Schwippert B, Tschope D, Schror K. Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Br J Clin Pharmacol 2001; 52: 333-336.
61. Eisert WG. Dipyridamole. In Platelets, Michelson AD (ed.). Academic Press: Amsterdam, 2002; 803-815.
62. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
63. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
64. National Institute for Health and Clinical Excellence (NICE). Clopidogrel and Modified-release Dipyridamole in the Prevention of Occlusive Vascular Events: Technology Appraisal 90. NICE: London, 2005.
65. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
66. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A, The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665-1673.
67. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717.
68. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-337.
69. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
70. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-2420.
71. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519-1521.
72. Kapetanakis EI, Medlam DA, Boyce SW, Haile E, Hill PC, Dullum MK et al. Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache? Eur Heart J 2005; 26: 576-583.
73. Spahn DR, Howell SJ, Delabays A, Chassot PG. Coronary stents and perioperative anti-platelet regimen: dilemma of bleeding and stent thrombosis. Br J Anaesth 2006; 96: 675-677.